

## REIMBURSEMENT POLICY STATEMENT GEORGIA MEDICAID

<b>Original Issue Date</b>	<b>Next Annual Review</b>	<b>Effective Date</b>
11/01/2017	03/01/2019	03/01/2018
<b>Policy Name</b>		<b>Policy Number</b>
Screening and Surveillance for Colorectal Cancer		PY-0404
<b>Policy Type</b>		
Medical	Administrative	Pharmacy
<b>REIMBURSEMENT</b>		

Reimbursement Policies prepared by CSMG Co. and its affiliates (including CareSource) are intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry-standard claims editing logic, benefits design and other factors are considered in developing Reimbursement Policies.

In addition to this Policy, Reimbursement of services is subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any federal or state coverage mandate, Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

This Policy does not ensure an authorization or Reimbursement of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced herein. If there is a conflict between this Policy and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

CSMG Co. and its affiliates may use reasonable discretion in interpreting and applying this Policy to services provided in a particular case and may modify this Policy at any time.

## Contents of Policy

<b><u>REIMBURSEMENT POLICY STATEMENT</u></b> .....	1
<b><u>TABLE OF CONTENTS</u></b> .....	1
<b><u>A. SUBJECT</u></b> .....	2
<b><u>B. BACKGROUND</u></b> .....	2
<b><u>C. DEFINITIONS</u></b> .....	2
<b><u>D. POLICY</u></b> .....	2
<b><u>E. CONDITIONS OF COVERAGE</u></b> .....	2
<b><u>F. RELATED POLICIES/RULES</u></b> .....	4
<b><u>G. REVIEW/REVISION HISTORY</u></b> .....	4
<b><u>H. REFERENCES</u></b> .....	4



## A. SUBJECT

### Screening and Surveillance for Colorectal Cancer

## B. BACKGROUND

Reimbursement policies are designed to assist you when submitting claims to CareSource. They are routinely updated to promote accurate coding and policy clarification. These proprietary policies are not a guarantee of payment. Reimbursement for claims may be subject to limitations and/or qualifications. Reimbursement will be established based upon a review of the actual services provided to a member and will be determined when the claim is received for processing. Health care providers and their office staff are encouraged to use self-service channels to verify member's eligibility.

It is the responsibility of the submitting provider to submit the most accurate and appropriate CPT/HCPCS code(s) for the product or service that is being provided. The inclusion of a code does not imply any right to reimbursement or guarantee claims payment.

CareSource will reimburse participating providers for medically necessary and preventive screening tests for colorectal cancer as required by state requirements through criteria based on recommendations from the U.S. Preventive Services Task Force (USPSTF) and the American College of Gastroenterology (ACG).

## C. DEFINITIONS

- See Screening and Surveillance for Colorectal Cancer medical policy, MM-0192

## D. POLICY

- I. CareSource does not require prior authorization for screening and diagnostic colonoscopies for participating providers.
- II. CareSource reimburses for screening and diagnostic colonoscopies according to CareSource Medical policy MM-0192. Members must meet the criteria found in medical policy MM-0192.
- III. When billing for screening and surveillance colorectal services, providers should use the appropriate CPT/HCPCS codes and modifiers, if applicable.

## E. CONDITIONS OF COVERAGE

Reimbursement is dependent on, but not limited to, submitting state Medicaid approved HCPCS and CPT codes along with appropriate modifiers, if applicable. Please refer to the state Medicaid fee schedules:

<https://www.mmis.georgia.gov/portal/Portals/0/StaticContent/Public/ALL/FEE%20SCHEDULES/Lab%20Max%20Allowable%20%2020170908145522.pdf>

<https://www.mmis.georgia.gov/portal/Portals/0/StaticContent/Public/ALL/FEE%20SCHEDULES/Schedule%20of%20%20Maximum%20%20Allowable%20%20Payments%20%20Physician%2020170922174435.pdf>

**The following list(s) of codes is provided as a reference. This list may not be all inclusive and is subject to updates. Please refer to the above referenced sources for the most current coding information.**

Code	Description
45330	Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
45331	Sigmoidoscopy, flexible; with biopsy, single or multiple



45332	Sigmoidoscopy, flexible; with removal of foreign body(s)
45333	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps
45335	Sigmoidoscopy, flexible; with directed submucosal injection(s), any substance
45338	Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
45340	Sigmoidoscopy, flexible; with transendoscopic balloon dilation
45341	Sigmoidoscopy, flexible; with endoscopic ultrasound examination
45342	Sigmoidoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s)
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)
45379	Colonoscopy, flexible; with removal of foreign body(s)
45380	Colonoscopy, flexible; with biopsy, single or multiple
45381	Colonoscopy, flexible; with directed submucosal injection(s), any substance
45382	Colonoscopy, flexible; with control of bleeding, any method
45384	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique
45386	Colonoscopy, flexible; with transendoscopic balloon dilation
45391	Colonoscopy, flexible; with endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures
45392	Colonoscopy, flexible; with transendoscopic ultrasound guided intramural or transmural fine needle aspiration/biopsy(s), includes endoscopic ultrasound examination limited to the rectum, sigmoid, descending, transverse, or ascending colon and cecum, and adjacent structures
81528	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result (Cologuard)
82270	Blood, occult, by peroxidase activity (e.g., guaiac), qualitative; feces, consecutive collected specimens with single determination, for colorectal neoplasm screening (i.e., patient was provided 3 cards or single triple card for consecutive collection)
82272	Blood, occult, by peroxidase activity (e.g., guaiac), qualitative, feces, 1-3 simultaneous determinations, performed for other than colorectal neoplasm screening
82274	Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations
G0328	Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous determinations



#### F. RELATED POLICIES/RULES

Screening and Surveillance for Colorectal Cancer, MM-0192

#### G. REVIEW/REVISION HISTORY

DATE		ACTION
Date Issued	11/01/2017	New Policy.
Date Revised		
Date Effective	03/01/2018	

#### H. REFERENCES

1. Schedule of Maximum Allowable Payments Physician July 2017. (2017, July). Retrieved 10/9/2017 from <https://www.mmis.georgia.gov/portal/Portals/0/StaticContent/Public/ALL/FEE%20SCHEDULES/Schedule%20of%20%20Maximum%20%20Allowable%20%20Payments%20%20Physician%2020170922174435.pdf>
2. Schedule of Maximum Allowable Payments Clinical Laboratory and Anatomical Pathology Services. (2017, October 1). Retrieved from <https://www.mmis.georgia.gov/portal/Portals/0/StaticContent/Public/ALL/FEE%20SCHEDULES/Lab%20Max%20Allowable%20%2020170908145522.pdf>

**The Reimbursement Policy Statement detailed above has received due consideration as defined in the Reimbursement Policy Statement Policy and is approved.**